BRCA2-Directed Therapy Case: Treating Metastatic Pancreatic Cancer

Recent News More News Gina Tomaine The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial. The addition of concurrent and adjuvant atezolizumab to standard chemoradiation did not improve survival outcomes for patients with limited-stage SCLC, according to results from the phase 3 NRG Oncology/Alliance LU005 trial. The addition of concurrent and... Oncology News Gina Tomaine Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results. Berzosertib plus topotecan did not yield meaningful clinical benefits for patients with relapsed, platinum-resistant SCLC compared with topotecan monotherapy, according to phase 2 study results. Berzosertib plus topotecan did... Oncology News Gina Tomaine Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a... Tarlatamab for patients with ES-SCLC and neuroendocrine lung cancer was associated with higher CRS and ICANS rates in real-world settings than in trials, while prophylactic tocilizumab may mitigate these toxicities, according to a... Tarlatamab for patients with... Oncology News Emily Estrada The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes. The all-oral combination of iberdomide, cyclophosphamide, and dexamethasone (IberCd) demonstrated a median progression-free survival and manageable safety in patients with R/R multiple myeloma previously exposed to multiple drug classes. The all-oral combination of... Oncology News Emily Estrada Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality. Among patients with myelofibrosis undergoing allogeneic transplantation, improved outcomes and long-term survival remain limited by high non-relapse mortality. Among patients with... Oncology News Emily Estrada Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and... Pacritinib therapy showed meaningful clinical benefit, including spleen size reduction, symptom improvement, and hematologic response regardless of the line of therapy, according to a real-world analysis of patients with myelofibrosis and... Pacritinib therapy showed... Oncology News Stephanie Holland Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors. Results from a phase 3 trial demonstrated that pegylated liposomal doxorubicin significantly prolonged PFS compared with placebo treatment among patients with advanced or refractory desmoid tumors. Results from a phase 3 trial... Oncology News Stephanie Holland Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion... Results from the phase 2 KANNON trial demonstrate that andamertinib shows promising antitumor activity among previously treated patients with locally advanced or metastatic non-small cell lung cancer harboring EGFR exon 20 insertion... Results from the phase 2 KANNON... Oncology Conference Coverage Stephanie Holland Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. Results from the phase 1/2 ReFocus study show that lirafugratinib demonstrates promising efficacy and safety among FGFR inhibitor-naive patients with advanced or metastatic cholangiocarcinoma harboring FGFR2 fusions or rearrangements. Results from the phase 1/2... Oncology News Gina Tomaine Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy. Results showed that eflornithine combined with lomustine significantly prolonged both progression-free and overall survival for patients with recurrent IDH-mutant, grade 3 astrocytoma, compared with lomustine monotherapy. Results showed that eflornithine... Oncology